SCHEMBL18035265

SCHEMBL18035265

[N-]=[N+]=NC(=O)C=Cc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.50
▸ HDAC1 Q13547 3/20 0.45
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ HDAC8 Q9BY41 1/20 0.45
▸ HRH3 Q9Y5N1 1/20 0.41
▸ PDE2A O00408 1/20 0.41
▸ GRIK1 P39086 1/20 0.41
▸ GRIK2 Q13002 1/20 0.41
▸ IP6K1 Q92551 1/20 0.40
▸ IP6K3 Q96PC2 1/20 0.40
▸ IP6K2 Q9UHH9 1/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ ESR1 P03372 1/20 0.38
▸ APP P05067 1/20 0.38
▸ MCHR1 Q99705 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16676476 1.00 CYP2D6 (0.50) CYP2D6HDAC1CA12CA1CA2
SCHEMBL16030403 0.81 STAT3 (0.38) CYP2D6HDAC1CA12CA1CA2
SCHEMBL16030404 0.81 STAT3 (0.38) CYP2D6HDAC1CA12CA1CA2
SCHEMBL15468099 0.81 CYP1A2 (0.60) HDAC1HDAC8CYP1A1CYP1B1MAOB
SCHEMBL15468100 0.81 CYP1A2 (0.60) HDAC1HDAC8CYP1A1CYP1B1MAOB
SCHEMBL13730037 0.79 HSD11B1 (0.56) KMT2AEGFRMEN1CYP1A1CYP1B1
SCHEMBL13730038 0.79 HSD11B1 (0.56) KMT2AEGFRMEN1CYP1A1CYP1B1
SCHEMBL11211973 0.78 CYP2D6 (0.60) CYP2D6HDAC1CA12CA1CA2
SCHEMBL11211974 0.78 CYP2D6 (0.60) CYP2D6HDAC1CA12CA1CA2
SCHEMBL584591 0.77 THRB (0.61) CYP2D6HDAC1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10005739-B2 Quinazolinone and isoquinolinone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2018-06-26 — — US disclosed
US-20160272595-A1 QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-09-22 — — US disclosed
EP-3061749-A1 QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2016-08-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272595-A1 QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE NQO2, SDHA, CYP3A5 CYP2D6 50/4885HDAC1 621/4885CA12 4299/4885
US-10005739-B2 Quinazolinone and isoquinolinone derivative NQO2, SDHA, CYP3A5 CYP2D6 50/4885HDAC1 621/4885CA12 4299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback